Pulmonary Delivery of Anticancer Drugs via Lipid-Based Nanocarriers for the Treatment of Lung Cancer: An Update
Lung cancer (LC) is the leading cause of cancer-related deaths, responsible for approximately 18.4% of all cancer mortalities in both sexes combined. The use of systemic therapeutics remains one of the primary treatments for LC. However, the therapeutic efficacy of these agents is limited due to the...
Main Authors: | Ibrahim M. Abdulbaqi, Reem Abou Assi, Anan Yaghmur, Yusrida Darwis, Noratiqah Mohtar, Thaigarajan Parumasivam, Fadi G. Saqallah, Habibah A. Wahab |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/14/8/725 |
Similar Items
-
Choice of nanocarrier for pulmonary delivery of cancer therapeutics
by: Wong, T.W
Published: (2020) -
Advances in Nanocarriers for Effective Delivery of Docetaxel in the Treatment of Lung Cancer: An Overview
by: S. Aishah A. Razak, et al.
Published: (2021-01-01) -
Recent Advances in Nanocarrier-Assisted Therapeutics Delivery Systems
by: Shi Su, et al.
Published: (2020-09-01) -
Targeted Delivery of Protein Drugs by Nanocarriers
by: Antonella Battisti, et al.
Published: (2010-03-01) -
Development of High Efficiency Dry Powder Inhalers for Use with Spray Dried Formulations
by: Farkas, Dale
Published: (2017)